Drug Profile
Capivasertib - AstraZeneca
Alternative Names: AZD 5363; TruqapLatest Information Update: 02 Apr 2024
Price :
$50
*
At a glance
- Originator Astex Therapeutics; Cancer Research Technology; The Institute of Cancer Research
- Developer AstraZeneca
- Class Antineoplastics; Piperidines; Pyrimidines; Pyrroles; Small molecules
- Mechanism of Action Proto oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered HER2 negative breast cancer
- Phase III Prostate cancer; Triple negative breast cancer
- Phase II Breast cancer; Endometrial cancer; Gastric cancer; Meningioma; Non-Hodgkin's lymphoma
- Phase I/II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
- Preclinical Diffuse large B cell lymphoma
- Discontinued Non-small cell lung cancer
Most Recent Events
- 27 Mar 2024 Registered for HER2-negative-breast-cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Recurrent, Second-line therapy or greater) in Japan (PO)
- 05 Dec 2023 Efficacy and adverse events data from a phase Ib/III CAPItello-292 trial in breast cancer presented at the 46th Annual San Antonio Breast Cancer Symposium (SABCS-2023)
- 05 Dec 2023 Updated efficacy and adverse events data from a phase III CAPItello-291 trial in Breast cancer presented at the 46th Annual San Antonio Breast Cancer Symposium (SABCS-2023)